Monetary Management Group Inc. Sells 1,000 Shares of Humana Inc. (NYSE:HUM)

Monetary Management Group Inc. cut its holdings in Humana Inc. (NYSE:HUM) by 31.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,137 shares of the insurance provider’s stock after selling 1,000 shares during the period. Monetary Management Group Inc.’s holdings in Humana were worth $542,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. FPC Investment Advisory Inc. purchased a new position in Humana in the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC bought a new position in shares of Humana in the fourth quarter worth approximately $30,000. LFA Lugano Financial Advisors SA increased its stake in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the period. OFI Invest Asset Management bought a new stake in Humana during the 4th quarter valued at $33,000. Finally, Atwood & Palmer Inc. boosted its position in Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Up 1.9 %

HUM stock opened at $290.83 on Friday. The business has a 50 day moving average of $265.56 and a 200 day moving average of $270.77. The firm has a market cap of $35.10 billion, a PE ratio of 29.23, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, research analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.22%. Humana’s dividend payout ratio is 35.58%.

Analysts Set New Price Targets

HUM has been the subject of several recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Barclays upped their price target on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Piper Sandler lifted their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Cantor Fitzgerald restated a “neutral” rating and set a $290.00 target price on shares of Humana in a report on Wednesday, February 12th. Finally, Mizuho lifted their price target on shares of Humana from $305.00 to $316.00 and gave the company an “outperform” rating in a report on Wednesday. Seventeen analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $284.25.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.